Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826445 | 0.90 | PSIP1 (0.40) | CYP2C19PSIP1RORC | |
| Methoxymethane SCHEMBL1826559 | 0.88 | PSIP1 (0.38) | CYP2C19PSIP1RORC | |
| SCHEMBL1823082 | 0.80 | CTSS (0.41) | MAPTCA1CA2 | |
| SCHEMBL6900972 | 0.75 | PSIP1 (0.42) | CYP2C19PSIP1RORC | |
| SCHEMBL1827681 | 0.73 | TDP1 (0.46) | KDM4EMEN1MAPTKMT2AAR | |
| SCHEMBL1826050 | 0.71 | TSHR (0.40) | TSHRTACR1ARCA1CA2 | |
| SCHEMBL11208770 | 0.71 | MAPK1 (0.52) | TSHRMAPTKMT2ACYP2C19 | |
| SCHEMBL27853835 | 0.69 | CA1 (0.48) | TSHRKDM4EMAPTKMT2AAR | |
| SCHEMBL1825974 | 0.69 | TSHR (0.43) | TSHRTACR1ARCA1CA2 | |
| SCHEMBL1823723 | 0.68 | CA1 (0.41) | MEN1KMT2ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161254-B1 | Intermediate for preparing a biaryl compound | SUMITOMO CHEMICAL CO (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-1481967-B1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7714157-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-2161254-A1 | Intermediate for preparing a biaryl compound | Sumitomo Chemical Company, Limited (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-20070270603-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-7271280-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1481967-A1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040158093-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158093-A1 | Process for preparing a biaryl compound | CYP1B1, REL, CYP2F1 | TSHR 1200/4885TACR1 1743/4885KDM4E 2554/4885 |
| US-20070270603-A1 | Process for preparing a biaryl compound | CYP4A11, CYP4B1, CYP51A1 | TSHR 2860/4885TACR1 2452/4885KDM4E 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.